Nautilus Biotechnology spent the better part of a decade selling investors on a single-molecule machine that would read the whole proteome. That Broadscale product is no longer on a next-year calendar. Second-quarter testing showed that assay-configuration changes did not lift probe-candidate performance enough to support general availability in 2027 at the company's own target specifications. Management is now moving most application-specific research effort onto targeted proteoform assays, the narrower measurements of protein isoforms and modification patterns that customers are actually requesting. The equity story flipped from whole-proteome instrument company to niche proteoform assay vendor that still hopes to sell a high-ticket box. Sequencing changed. Conviction about the underlying method did not, at least in management's telling.
First revenue arrived in the same quarter, and it is not a commercial launch. Nearly all of the print is Michael J. Fox Foundation grant income for an alpha-synuclein assay, plus a thin early-access service invoice from Baylor College of Medicine. Operating costs fell, cash and investments still sit well above one hundred million, and the residual market value after that cash is close to nothing. The tape is already back under the Nasdaq minimum bid line that forced a Capital Market transfer last autumn. Shareholders are no longer underwriting a 2027 whole-proteome launch. They are underwriting a slower, narrower path whose first product invoices are still a year away.
The question for the next several quarters is whether proteoform uniqueness, now backed by a Nature Methods tau paper, converts into signed early-access work and then into Voyager pre-orders before the company taps a freshly filed at-the-market program. Management still targets pre-orders early next year and instrument shipments later in 2027, timed to tau and AKT1 kits. Cash is described as lasting into early 2028, with a raise anticipated before the instrument ships. Does the market fund that raise at a price that leaves common holders a real claim, or does the platform remain a call option that expires into dilution?